| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2011.11.051 |
| P698 | PubMed publication ID | 22107850 |
| P50 | author | Lars Østergaard | Q55232366 |
| Sven Arne Silfverdal | Q71500029 | ||
| P2093 | author name string | Johan Berglund | |
| Jacqueline M Miller | |||
| Veronique Bianco | |||
| Carl-Erik Flodmark | |||
| Yaela Baine | |||
| Christina West | |||
| P2860 | cites work | Prospects for vaccine prevention of meningococcal infection | Q24537338 |
| Review of meningococcal group B vaccines | Q33646965 | ||
| Importance of complement source in measuring meningococcal bactericidal titers | Q33999159 | ||
| Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection | Q34006352 | ||
| Combining hepatitis A and B vaccination in children and adolescents | Q34189159 | ||
| Meningococcal disease | Q34239234 | ||
| Development of vaccines against meningococcal disease | Q34623334 | ||
| A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine | Q35791752 | ||
| Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England | Q35923728 | ||
| Meningococcal surrogates of protection--serum bactericidal antibody activity | Q36065385 | ||
| Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age | Q36153910 | ||
| Long-term protection in children with meningococcal C conjugate vaccination: lessons learned | Q36690297 | ||
| Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study | Q36738155 | ||
| The nature and consequences of intra- and inter-vaccine interference | Q36846055 | ||
| Quadrivalent meningococcal conjugate vaccines. | Q37499437 | ||
| Glycoconjugate vaccines and immune interference: A review | Q37769874 | ||
| Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents | Q38381404 | ||
| Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults | Q38905553 | ||
| Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial | Q38927375 | ||
| Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial | Q40329667 | ||
| Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants | Q44256464 | ||
| Invasive meningococcal disease in adolescents and young adults | Q44365223 | ||
| Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile | Q44599973 | ||
| Global epidemiology of meningococcal disease. | Q44677055 | ||
| A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents | Q45184665 | ||
| Neisseria vaccines 2007. | Q46582106 | ||
| Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. | Q51988230 | ||
| Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years | Q60469320 | ||
| Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. | Q64901018 | ||
| A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera | Q70263781 | ||
| Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age | Q83106446 | ||
| An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children | Q83656070 | ||
| A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children | Q84840768 | ||
| Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age | Q84862846 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular medicine | Q3523816 |
| tetanus vaccine | Q5861101 | ||
| infectious disease | Q18123741 | ||
| P304 | page(s) | 774-783 | |
| P577 | publication date | 2011-11-19 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial | |
| P478 | volume | 30 |
| Q37600163 | Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age. |
| Q91701855 | Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence |
| Q91851247 | Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents |
| Q47672096 | Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review |
| Q37252405 | Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years |
| Q38066532 | Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™). |
| Q38743826 | Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence |
| Q27028161 | Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease |
| Q89810545 | Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen |
| Q36825737 | Routinely vaccinating adolescents against meningococcus: targeting transmission & disease |
| Q84773798 | [Meningococcal vaccines: from polysaccharide to conjugate vaccines] |
Search more.